ATE223702T1 - Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien - Google Patents

Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

Info

Publication number
ATE223702T1
ATE223702T1 AT94930768T AT94930768T ATE223702T1 AT E223702 T1 ATE223702 T1 AT E223702T1 AT 94930768 T AT94930768 T AT 94930768T AT 94930768 T AT94930768 T AT 94930768T AT E223702 T1 ATE223702 T1 AT E223702T1
Authority
AT
Austria
Prior art keywords
adjuvants
compositions
microcapsulating
adjuvant
microspheres
Prior art date
Application number
AT94930768T
Other languages
English (en)
Inventor
Jeffrey L Cleland
Amy Lim
Michael Frank Powell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE223702T1 publication Critical patent/ATE223702T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94930768T 1993-10-22 1994-10-13 Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien ATE223702T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14134193A 1993-10-22 1993-10-22
US14333293A 1993-10-25 1993-10-25
PCT/US1994/011674 WO1995011008A2 (en) 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of adjuvants

Publications (1)

Publication Number Publication Date
ATE223702T1 true ATE223702T1 (de) 2002-09-15

Family

ID=26839008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930768T ATE223702T1 (de) 1993-10-22 1994-10-13 Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien

Country Status (9)

Country Link
EP (1) EP0724431B1 (de)
JP (1) JPH09504523A (de)
AT (1) ATE223702T1 (de)
AU (1) AU7979094A (de)
CA (1) CA2172507C (de)
DE (1) DE69431358T2 (de)
DK (1) DK0724431T3 (de)
ES (1) ES2182850T3 (de)
WO (1) WO1995011008A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391445C (zh) * 1996-01-24 2008-06-04 美国政府陆军部 新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球
JP3698721B2 (ja) * 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
DE69415684T2 (de) * 1993-10-22 1999-06-10 Genentech Inc., San Francisco, Calif. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
EP2283821A1 (de) * 1993-11-19 2011-02-16 Alkermes, Inc. Herstellung biodegradierbarer Mikroteilchen, die ein biologisch aktives Mittel enthalten
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
DE69841708D1 (de) * 1997-02-06 2010-07-22 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
WO2000012124A1 (en) 1998-09-01 2000-03-09 Elan Corporation, Plc Oral vaccine compositions
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2001058466A1 (en) * 2000-02-08 2001-08-16 Institute Of Molecular Agrobiology Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria
ES2160089B1 (es) * 2000-03-15 2002-05-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos.
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ATE489968T1 (de) * 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
HUE031550T2 (en) * 2007-06-06 2017-07-28 Debiopharm Res & Mfg Sa Slow release pharmaceutical composition made of microparticles
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2244695A1 (de) 2007-12-07 2010-11-03 Novartis AG Zusammensetzungen zur induktion von immunantworten
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2308478A1 (de) * 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Abgabesystem zur verzögerten Freisetzung von Calciumkanalblocker Arzneistoffen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion

Also Published As

Publication number Publication date
EP0724431A1 (de) 1996-08-07
WO1995011008A2 (en) 1995-04-27
DE69431358D1 (de) 2002-10-17
JPH09504523A (ja) 1997-05-06
ES2182850T3 (es) 2003-03-16
DE69431358T2 (de) 2003-06-05
WO1995011008A3 (en) 1996-09-19
CA2172507A1 (en) 1995-04-27
CA2172507C (en) 2008-12-02
AU7979094A (en) 1995-05-08
DK0724431T3 (da) 2003-01-06
EP0724431B1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
PT758248E (pt) Formulacoes para o factor ix
ES2092306T3 (es) Adyuvante para vacunas.
TR200403064T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler.
DE59400126D1 (de) Verfahren zur Herstellung von amphoteren Tensiden
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
FI943141A7 (fi) Hitaasti vapautuvat koostumukset ja menetelmä farmaseuttisten koostumusten valmistamiseksi
FI945476L (fi) Hitaasti vapautuvat koostumukset ja menetelmä farmaseuttisten koostumusten valmistamiseksi
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
NO962073L (no) Amfifiliske imidazoliniumderivater
ITMI920678A1 (it) Dispositivo di ancoraggio, per esempio per componenti di mobili e simili
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
BG103141A (en) Composition of a malaria vaccine
DE69221745D1 (de) Verfahren zur kombinierten Herstellung von organischen Zusammenstellungen und Energie
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE69313297D1 (de) Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
MX9100886A (es) Activador de plasminogeno hibrido,procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
DE59305210D1 (de) Verfahren zur Herstellung von Diphenylaminen
DE68914620D1 (de) Verfahren zur Herstellung der Restriktionsendonucklease PvuI.
DE3851541D1 (de) Propylen-äthylen-kopolymer-zusammensetzung und verfahren zur herstellung.
MX9203574A (es) Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen.
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification